A new front in the debate over HPV vaccines for boys: Studies hint at broader benefits from Gardasil

Cancer Cytopathology

Volumn 118, Issue 6, 2010, Pages 413-414

  Nelson, Bryn ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; IMMUNOLOGY; MALE; NASOPHARYNX TUMOR; NOTE; PUBLIC HEALTH; VACCINATION;

COST-BENEFIT ANALYSIS; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS VACCINES; PUBLIC HEALTH; VACCINATION;

EID: 79952222948     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20128     Document Type: Note

References (5)

1. Palefsky J. Efficacy of Gardasil in men aged 16-26 years naïve to vaccine HPV types at baseline: The latest data. Paper presented at: European Research Organization on Genital Infection and Neoplasia conference; February 20,2010; Monte Carlo. Monaco.
2. SEER Stat Fact Sheets: Overview, http://seer.cancer.gov/statfacts/html/ anus.html. Accessed October 26.2010.
3. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in o human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.
4. D'Souza G, KreimerAR, Viscidi R.etal. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356: 1944-1956.
5. Sturgis EM, Dahlstrom KR. HPV vaccinations: inaccurate assumptions about oropharyngeal cancer. BMJ. 2009; 339;b452S.